These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 489428)

  • 1. Multiple myeloma: results with the M-2 protocol in a community hospital.
    Miller S; Perrotta AL
    J Am Osteopath Assoc; 1979 Aug; 78(12):857-64. PubMed ID: 489428
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts in cancer. Multiple myeloma.
    McIntyre OR
    N Engl J Med; 1979 Jul; 301(4):193-6. PubMed ID: 377077
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy of plasma-cell myeloma.
    Case DC
    N Engl J Med; 1980 Feb; 302(7):407. PubMed ID: 6986024
    [No Abstract]   [Full Text] [Related]  

  • 10. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 14. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
    Raya Sánchez JM; González Brito G; Marsá Vila L; Brito Barroso ML; Hernández Nieto L
    Sangre (Barc); 1991 Oct; 36(5):434-5. PubMed ID: 1816642
    [No Abstract]   [Full Text] [Related]  

  • 18. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acute ischemia and heart failure during cyclic chemotherapy in a patient with plasmocytic myeloma].
    Drzewoski J; Olszańska-Skorek T; Urbańska-Ryś H; Kończalik P; Krykowski E
    Pol Tyg Lek; 1990 Dec 17-31; 45(51-52):1056-8. PubMed ID: 2098746
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
    Strobel ES; Bauchmüller K; Schmitt-Gräff A; Engelhardt M
    Ann Hematol; 2005 Nov; 84(12):830-2. PubMed ID: 16132908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.